Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV

The information in the brief version is excerpted directly from the full-text guidelines. The brief version is a compilation of the tables and boxed recommendations.

  •   Table of Contents

Download Guidelines

Appendix B: Panel Roster and Financial Disclosures

Human Papillomavirus

Last Updated: January 1, 2020; Last Reviewed: August 1, 2019

Human Papillomavirus Disease
Member Financial Disclosure
Company Relationship
Brown, Darron Indiana University School of Medicine Merck Research Support
Productive Data Solutions, Inc. Consultant
Cu-Uvin, Susan* Brown University AIDS Malignancy Consortium Data Safety Monitoring Board
National Institutes of Health Research Support
United Nations Population Fund Research Support
Dunne, Eileen Centers for Disease Control and Prevention None N/A
Einstein, Mark Rutgers New Jersey Medical School Advaxis Research Support
Altum Pharma Consultant
AstraZeneca Research Support
Becton-Dickinson Consultant
Cynvec Consultant
Hologic Consultant
Inovio Research Support
J&J Research Support
Merck Consultant
Papivax Consultant
PDS Biotechnologies Advisory Board
Pfizer Research Support
Roche Research Support
Massad, L. Stewart Washington University School of Medicine None N/A
Moscicki, Anna Barbara University of California, Los Angeles Antiva Advisory Board
GlaxoSmithKline Advisory Board
Merck Advisory Board
Patient-Centered Outcomes Research Institute Research Support
Palefsky, Joel University of California, San Francisco Antiva Biosciences Research Support
Janssen Pharmaceuticals Speakers Bureau
Merck Advisory Board, Research Support
Ubiome Advisory Board, Equity Interest
Vir Biotechnology Consultant, Equity Interest
Virion Therapeutics Advisory Board, Equity Interest
Stier, Elizabeth Boston University Medical Center Antiva Consultant
Inovio Research Support
National Institutes of Health Research Support
Strickler, Howard Albert Einstein College of Medicine None N/A
Weiser, John Centers for Disease Control and Prevention None N/A
Wilkin, Timothy Weill Cornell Medical College GlaxoSmithKline/ViiV Consultant, Research Support
* Group lead

Note: Members were asked to disclose all relationships from 12 months prior to the updated date. The period of reporting was from August 1, 2018, through August 1, 2019.

Download Guidelines